Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer

References

• Jemal A, Bray F, Center MM, et al. Global cancer statistics, 2011. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Bhat SA, Mir MUR, Majid S, et al. Diagnostic utility of glycosyltransferase mRNA expression in gastric cancer. Hematol Oncol Stem Cell Ther. 2018;11:158–168.
   PubMedGoogle Scholar
• Ren H, Xu Z, Guo W, et al. Rab3IP interacts with SSX2 and enhances the invasiveness of gastric cancer cells. Biochem Biophys Res Commun. 2018;503:2563–2568.
   PubMed Web of Science ®Google Scholar
• Kato Y, Yashiro M, Noda S, et al. Establishment and characterization of a new hypoxia-resistant cancer cell line, OCUM-12/Hypo, derived from a scirrhous gastric carcinoma. Br J Cancer. 2010;102:898–907.
   PubMed Web of Science ®Google Scholar
• Zhang W, Song Y. LINC00473 predicts poor prognosis and regulates cell migration and invasion in gastric cancer. Biomed Pharmacother. 2018;107:1–6.
   PubMed Web of Science ®Google Scholar
• Pruszynski K, van Sandick JW, Mielko J, et al. Current challenges in gastric cancer surgery: European perspective. Surg Oncol. 2018;27:650–656.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Q, Feng L, et al. Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement. Nano Today. 2018;21:55–73.
   Web of Science ®Google Scholar
• Meng W, Xue S, Chen X. The role of CXCL12 in tumor microenvironment. Gene. 2018;641:105–110.
   PubMed Web of Science ®Google Scholar
• Lee NH, Nikfarjam M, He H. Functions of the CXC ligand family in the pancreatic tumor microenvironment. Pancreatology. 2018;18:705–716.
   PubMed Web of Science ®Google Scholar
• Servais C, Erez N. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumor-related inflammation. J Pathol. 2013;229:198–207.
   PubMed Web of Science ®Google Scholar
• Grimm S, Jennek S, Singh R, et al. Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop. Exp Cell Res. 2015;335:1–11.
   PubMed Web of Science ®Google Scholar
• Tripathi M, Billet S, Bhowmick NA. Understanding the role of stromal fibroblasts in cancer progression. Cell Adh Migr. 2012;6:231–235.
   PubMed Web of Science ®Google Scholar
• Saigusa S, et al. Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol. 2011;38:655–663.
   PubMed Web of Science ®Google Scholar
• Ernsting EJ, Hoang B, Lohse I, et al. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. J Control Release. 2015;206:122–130.
   PubMed Web of Science ®Google Scholar
• Leef G, Thomas SM. Molecular communication between tumor-associated fibroblasts and head and neck squamous cell carcinoma. Oral Oncol. 2013;49:381–386.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res. 2014;26:104–111.
   PubMed Web of Science ®Google Scholar
• Robert C, Soria JC, Eggermont AMM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer. 2013;49:2968–2971.
   PubMed Web of Science ®Google Scholar
• Alaghehbandan R, Stehlik J, Trpkov K, et al. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol. 2017;29:17–22.
   PubMed Web of Science ®Google Scholar
• Okuma Y, Wakui H, Utsumi H, et al. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer. Clin Lung Cancer. 2018;19:410–417.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim S, Lee HS, et al. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecol Oncol. 2018;149:381–387.
   PubMed Web of Science ®Google Scholar
• Shiraliyeva N, Friedrichs J, Buettner R, et al. PD-L1 expression in HNPCC-associated colorectal cancer. Pathol Res Practice. 2017;213:1552–1555.
   PubMed Web of Science ®Google Scholar
• Baptista MZ, Sarian LO, Derchain S, et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Human Pathol. 2016;47:78–84.
   PubMed Web of Science ®Google Scholar
• Meng X, Liu Y, Zhang J, et al. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: new development and challenges. Cancer Lett. 2017;405:29–37.
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259–271.
   PubMed Web of Science ®Google Scholar
• Vicent S, Sayles LC, Vaka D, et al. Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 2012;72:5744–5756.
   PubMed Web of Science ®Google Scholar
• Lin ZY, Chuang YH, Chuang WL. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL-6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells. Biomed Pharmacother. 2012;66:525–529.
   PubMed Web of Science ®Google Scholar
• Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22:1367–1373.
   PubMed Web of Science ®Google Scholar
• de Haas S, Delmar P, Bansal AT, et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis. 2014;17:909–920.
   PubMed Web of Science ®Google Scholar
• Noguchi E, Saito N, Kobayashi M, et al. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression. Mol Med Rep. 2015;11:3423–3431.
   PubMed Web of Science ®Google Scholar
• Lu Y, Tang L, Zhang Q, et al. MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9. Artif Cells Nanomed Biotechnol. 2018;46:980–984.
   PubMed Web of Science ®Google Scholar
• Jotzu C, Alt E, Welte G, et al. Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor-derived factors. Anal Cell Pathol (Amst). 2010;33:61–79.
   PubMed Web of Science ®Google Scholar
• Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335–348.
   PubMed Web of Science ®Google Scholar
• Yu Y, Xiao C-H, Tan L-D, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signaling. Br J Cancer. 2014;110:724–732.
   PubMed Web of Science ®Google Scholar
• Nakazawa K, Yashiro M, Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 2003;63:8848–8854.
   PubMed Web of Science ®Google Scholar
• Zhi K, Shen X, Zhang H, et al. Cancer-associated fibroblasts are positively correlated with metastatic potential of human gastric cancers. J. Exp. Clin. Cancer Res. 2010;8:66.
   Web of Science ®Google Scholar
• Jung DW, et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int J Cancer. 2010;127:322–344.
   Web of Science ®Google Scholar
• Gharaati-Far N, Tohidkia MR, Dehnad A, et al. Efficiency and cytotoxicity analysis of cationic lipids-mediated gene transfection into AGS gastric cancer cells. Artif Cells Nanomed Biotechnol. 2018;46:1001–1008.
   PubMed Web of Science ®Google Scholar
• Wu M-H, Hong H-C, Hong T-M, et al. Targeting galectin-1 in carcimoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res. 2011;17:1306–1316.
   PubMed Web of Science ®Google Scholar
• Johanna AJ, Jeffrey WP. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–251.
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293–12297.
   PubMed Web of Science ®Google Scholar
• Lei Z, Tan IB, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3K inhibitor and 5-fluorouracil. Gastroenterology. 2013;145:554–565.
   PubMed Web of Science ®Google Scholar
• Scherz-Shouval R, Santagata S, Mendillo ML, et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014;158:564–578.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Bu Z, Liu X, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Clin J Cancer Res. 2014;26:104–111.
   Google Scholar
• Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer. 2008;23:57.
   Web of Science ®Google Scholar
• Alsuliman A, Colak D, Al-Harazi O, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer. 2015;14:149.
   PubMed Web of Science ®Google Scholar
• Muro K, Bang Y, Shankaran V, et al. IBA15A phase IB study of pembrolizumab (PEMBRO;MK-3475) in patients (PTS) with advanced gastric cancer. Ann Oncol. 2014;(Suppl. 4):415–438.
   Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537–1344.
   PubMed Web of Science ®Google Scholar
• Cho YA, Yoon HJ, Lee JI, et al. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011;47:1148–1153.
   PubMed Web of Science ®Google Scholar